Inclusion Criteria

Inclusion critera:

- Patients ≥ 18 years with classical HL relapsing or refractory after at least 1 prior
systemic therapy. Patients must have relapsed after high-dose therapy with ASCT, or
have been deemed ineligible for high-dose therapy with ASCT

- ECOG performance status ≤ 3

- Measurable nodal disease: 1 cm in the longest transverse diameter and clearly
measurable in at least two perpendicular dimensions, as determined by CT scan (MRI is
allowed only if CT scan cannot be performed).

- Patient has the following laboratory values:

- Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L [SI units 1.0 x 10^9/L]

- Platelet count ≥ 75 x 10^9/L]

- Serum creatinine ≤ 1.5 x upper limit of normal (ULN)

- Serum bilirubin ≤ 1.5 x ULN (or ≤ 3.0 x ULN, if patient has Gilbert syndrome)

- AST/SGOT and/or ALT/SGPT ≤ 2.5 x ULN or ≤ 5.0 x ULN if the transaminase
elevation is due to liver disease involvement

- Signed written informed consent

- Life expectancy ≥ 3 months

- Corrected QT interval ≤ 450 mSec

- Men and women of childbearing potential must agree to use an adequate method of
contraception during the study treatment and for at least 1 week after the last study
drug administration

- The patient must be covered by a social security system (for inclusions in France)

Exclusion criteria:

- Previous treatment with ruxolitinib or another JAK inhibitor

- Contraindication to ruxolitinib

- Patient received chemotherapy or radiotherapy or any investigational drug within 14
days prior to starting study drug or whose side effects of such therapy have not
resolved to ≤ grade 1

- Patient treated with allogeneic hematopoietic stem cell transplant who is currently
on, or has received immunosuppressive therapy within 90 days prior to start of
screening and/or have ≥ Grade 2 graft versus host disease (GvHD).

- Patient with prior history of another active primary malignancy ≤ 2 years before
study entry, with the exception of non-melanoma skin cancer, and carcinoma in situ of
uterine cervix

- Any serious active disease or co-morbid medical condition that, according to the
investigator's decision, will substantially increase the risk associated with the
subject's participation in the study.

- Uncontrolled infectious disease, including active HBV infection defined by either
detection of HBs Antigen or presence of anti HBc antibody without detectable anti HBs
antibody.

- HIV, HCV or HTLV serology positivity and/or documented infection with active
hepatitis B

- Prior history of CNS involvement with lymphoma

- Pregnant or lactating woman

- Adult patient unable to provide informed consent because of intellectual impairment,
any serious medical condition, laboratory abnormality or psychiatric illness.